(2) why the publication of her Department’s consultation on branded generic medicines has been delayed until after the Office of Fair Trading’s report on the pharmaceutical price regulation scheme in 2007; and if she will make a statement;
(3) whether the Department’s consultation on branded generic medicines will be made public; and if she will make a statement;
(4) what meetings she has held with interested parties on the delay in the publication of the Department’s consultation on generic medicines; and if she will make a statement.
The Department will not be able to determine what savings may be made by the national health service until such time as a number of complex issues raised by the consultation process have been resolved. It will also be necessary to consider these issues in the context of any conclusions reported in the Office of Fair Trading study into the pharmaceutical price regulation scheme (PPRS).
A decision has therefore been taken to defer any final conclusion until the Department receives the report on the PPRS which is expected in the first quarter of 2007.
A summary will be reported when the consultation is formally concluded.
No ministerial meeting has been held to inform interested parties, but these organisations have been advised of the delay.